BJUI provides the very highest standard of research and clinical information for the urological community. It also promotes awareness of new advances and supports the best practice in urology with a truly international range of published papers.
The Prostate is a peer-reviewed journal dedicated to original studies on Prostate and the male accessory glands. It presents comprehensive coverage of clinical, endocrinologic, and biochemical studies and significant case descriptions.
International Journal of Urology, publishes articles of scientific excellence in urology. It publishes high quality research ranging from experimental studies conducted in the laboratory to applied studies aimed at clinicians.
A number of approved treatment options are available for the management of metastatic castration-resistant prostate cancer such as chemotherapies (docetaxel, cabazitaxel), androgen receptor (AR)-targeted therapies (enzalutamide, abiraterone), a radioisotope (radium-223) and a cancer vaccine (sipuleucel-T).
A possibility exists that multiple chronic condition (MCC) patients are at increased risk of developing new, recurrent, or worsening urolithiasis, keeping in mind the risk factors for stone disease. Rezaee ME and co-authors carried out an investigation to evaluate the relationship between MCCs and urolithiasis.
Cho MC and co-authors conducted a clinical study that was aimed to investigate perceived ejaculatory function/satisfaction before treatment for lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) and to identify associations between specific categories of ejaculatory dysfunctions (EjDs) and LUTS.